.jpg)
Things continue to change for RSA’s UK and international division.
After rumours swirled that the company was reviewing its commercial business last month, the insurance giant has today revealed its commitment to the sector with plans to merge two divisions.
Commercial Risk Solutions (CRS) and Global Risk Solutions (GRS) will now come together as a single business unit focused on commercial lines with Rob Gibbs, the current managing director of CRS, moving into the role of MD of RSA commercial lines. The move also means that current MD of GRS Tony Buckle will leave the firm after a handover period.
“RSA’s commercial insurance offer is well respected in the market for its customer focus and expertise,” said Gibbs. “I am looking forward to building on those strong foundations to deliver even better customer and shareholder value.”
Prior to the merger the commercial division operated as two separate businesses – CRS focusing on UK domestic risks and delegated market authorities with GRS dealing with multinational corporate clients, along with specialty business written from the London market and across RSA’s European branches. Now, chief executive of RSA UK and International Scott Egan has explained that the unified division will have oversight of all commercial risks across the broker market and delegated authorities. The idea is to simplify processes and cut out duplication.
“We’ve made a number of changes to our UK business over the past 12 months,” he said. “The creation of single commercial lines business reflects our intent to be a more customer focused, simpler organisation.
“Rob is an experienced leader with a fantastic track record of delivery and a deep understanding of the commercial insurance market. I’m delighted he will be taking on this role. Sincere thanks are due to Tony for the hard work he has put into both serving our customers and brokers and reshaping the GRS business since he joined us in 2018.”
The merger of the commercial division follows on from RSA significantly reducing its London Market and specialty risk portfolios, with Gibbs’ appointment remaining subject to regulatory approval.
